FOR IMMEDIATE RELEASE:
CELSION FEATURED ON FRONT PAGE OF INVESTOR'S BUSINESS DAILY FOR
ADVANCED THERAPY TO HELP COMMON PROSTATE WOES FROM AGING
-- Company has FDA Approval to Begin Expanded Study of its IDE-approved
System --
Columbia, MD - November 17, 1999: Celsion Corporation (OTC BB: CELN) was
featured today on the front page of Investor's Business Daily for its
advanced benign prostatic hyperplasia (BPH) treatment system, which is
designed to treat this common prostate condition that affects 50 percent of
men over the age of 50.
Earlier this year the Company successfully completed Phase I clinical studies
of its BPH system, which has an Investigational Device Exemption (IDE) from
the U.S. Food and Drug Administration (FDA). Celsion also received approval
this year from the FDA to begin an expanded study of its BPH treatment with a
revised design to shorten the treatment period.
Today's article in Investor's Business Daily drew attention to the prevalence
of BPH and the fact that men suffering from the condition now have access to
new treatments that "dramatically impact your quality of life," as compared
to common treatments that involve daily medication or surgery.
In the feature on BPH, the journal also highlighted Celsion's system for its
unique design to use microwave thermotherapy in a walk-in, one-hour treatment
that, unlike many competitors' systems, does not require a post-therapy
catheter.
Celsion Corporation is a research and development company dedicated to
commercializing medical treatment systems for cancer and other diseases using
focused heat delivered by patented microwave technology. Clinicals and
further development of the Company's treatment systems are being conducted by
leading institutions such as the Columbia Hospital (a Columbia/HCA Healthcare
member), Duke University, Duke University Medical Center, Harbor UCLA Medical
Center, Massachusetts Institute of Technology and Montefiore Medical Center.
###
Forward-looking statements in this release are made pursuant to the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risks
and uncertainties, including, without limitation, possible changes in cost of
materials, expense items, capital expenditures, capital structure, and other
financial items; introduction of new products and possible acquisitions of
assets or businesses; possible actions by customers, suppliers, competitors,
regulatory authorities; and other risks detailed from time to time in the
Company's periodic reports filed with the Securities and Exchange Commission |
